LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Strona główna・Stock List・Gilead Sciences Inc.

Gilead Sciences Inc.

Closed

Sector Healthcare

78.71 0.01

Buy Sell

Overview

Share price change

24h

Current

Min

78.47

Max

78.83

Key metrics
By Trading Economics
Income	5.8B 1.6B
Sales	314M 7B
P/E Sector Avg	190.58 103.001
EPS	2.01
Profit margin	23.057
Employees	18,000
EBITDA	6.5B 3B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+5.73 upside

Dividends
By Dow Jones
Next Earnings	5 lis 2024
Next Dividend date	27 wrz 2024
Next Ex Dividend date	13 wrz 2024

Market Stats
By TradingEconomics
Market Cap	99B
Previous open	78.7
Previous close	78.71

News Sentiment

By Acuity

29%

71%

53 / 365 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

77.12 / 79.4 Support & Resistance

Gilead Sciences Inc. Chart

Related News

8 sie 2024, 20:49 UTC

Earnings

Gilead Sciences Posts Higher 2Q Profit, Revenue on Increased Sales

25 kwi 2024, 20:39 UTC

Earnings

Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges

28 mar 2024, 13:35 UTC

Major Market Movers

Xilio Shares Take Flight Premarket After Gilead Deal

9 sie 2024, 20:12 UTC

Earnings

Gilead Stock Dips As 'Non-Core' Products Drive Its Second-Quarter Beat -- IBD

9 sie 2024, 09:00 UTC

Top News

These Stocks Are Moving the Most Today: Expedia, Paramount, E.l.f. Beauty, Doximity, Rocket Lab, Gilead, and More -- Barrons.com

8 sie 2024, 20:03 UTC

Top News

Earnings

Gilead Boosts Earnings Outlook as Stock Battles Back from Cancer Disappointment -- Barrons.com

8 sie 2024, 20:03 UTC

Earnings

Gilead Sciences Sees FY24 EPS 0c-EPS 30c >GILD

8 sie 2024, 20:03 UTC

Earnings

Gilead Sciences Sees 3Q Adj EPS $3.60-Adj EPS $3.90 >GILD

8 sie 2024, 20:02 UTC

Earnings

Gilead Sciences 2Q Rev $7B >GILD

8 sie 2024, 20:02 UTC

Earnings

Gilead Sciences 2Q Adj EPS $2.01 >GILD

8 sie 2024, 20:02 UTC

Earnings

Gilead Sciences 2Q EPS $1.29 >GILD

8 sie 2024, 20:02 UTC

Earnings

Gilead Sciences 2Q Net $1.61B >GILD

20 cze 2024, 20:16 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 cze 2024, 18:09 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 cze 2024, 16:24 UTC

Earnings

Gilead Stock Jumps. Its Twice-Yearly Shot Prevents HIV. -- Barrons.com

20 cze 2024, 11:00 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

25 kwi 2024, 20:41 UTC

Earnings

Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again -- IBD

25 kwi 2024, 20:10 UTC

Earnings

Gilead Sciences Cuts FY View To Adj EPS $3.45-Adj EPS $3.85 >GILD

25 kwi 2024, 20:10 UTC

Earnings

Gilead Sciences Cuts FY View To EPS 10c-EPS 50c >GILD

25 kwi 2024, 20:09 UTC

Earnings

Gilead Sciences Backs FY Product Sales $27.1B-$27.5B >GILD

25 kwi 2024, 20:08 UTC

Earnings

Gilead Closed CymaBay Acquisition Resulting in $3.9 B Acquired IPR&D Chg, or $3.14 Diluted EPS Impact

25 kwi 2024, 20:07 UTC

Earnings

Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss? -- IBD

25 kwi 2024, 20:03 UTC

Top News

Earnings

Gilead Beats Earnings Expectations After Rocky Quarter -- Barrons.com

25 kwi 2024, 20:02 UTC

Earnings

Gilead Sciences 1Q Loss $4.17B >GILD

25 kwi 2024, 20:02 UTC

Earnings

Gilead Sciences 1Q Loss/Shr $3.34 >GILD

25 kwi 2024, 20:02 UTC

Earnings

Gilead Sciences 1Q Adj Loss/Shr $1.32 >GILD

25 kwi 2024, 20:02 UTC

Earnings

Gilead Sciences 1Q Rev $6.7B >GILD

22 mar 2024, 13:18 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences Announces Completion Of Acquisition Of CymaBay >GILD CBAY

11 mar 2024, 12:26 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Other Conditions Remain to Be Satisfied, Including, Among Others, a Minimum Tender of Shrs of Common Stk of CymaBay Representing a Majority of the Total Number of Outstanding Shrs of Common Stk of CymaBay >GILD

11 mar 2024, 12:26 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Expiration of the HSR Waiting Period Satisfies One of the Conditions to Consummate the Tender Offer >GILD

Peer Comparison

Price change

Gilead Sciences Inc. Forecast

Price Target

By TipRanks

5.73% upside

12 Months Forecast

Average 83.28 USD 5.73%

High 95 USD

Low 70 USD

Based on 21 Wall Street analysts offering 12 month price targets forGilead Sciences Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

21 ratings

Buy

Hold

Sell

Based on 21 analysts giving stock ratings to Gilead Sciences Inc. - Dist in the past 3 months.

Technical Score

By Trading Central

77.12 / 79.4Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

53 / 365 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Gilead Sciences Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.